Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
AstraZeneca released positive data from two clinical trials of roxadustat in anemia and of the company’s study of Lynparza in ovarian cancer.
China became the first country to approve a new anemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.
Months after partnering with Sanofi on infectious diseases, Germany-based Evotec formed another significant partnership with Novo Nordisk.
Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.
Akebia Therapeutics announced a merger agreement with Keryx Biopharmaceuticals to create a company expected to be a leader in the development of renal disease therapies.
Boehringer Ingelheim and Eli Lilly announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes.
Tricida reported that it closed an oversubscribed Series D financing worth $57.5 million. The round brings the company’s total capital raised to $153.5 million.
Shares of pain-relief company Cara Therapeutics were up more than 16 percent after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.